MCID: HYP005
MIFTS: 56

Hypokalemia

Categories: Blood diseases, Endocrine diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypokalemia

MalaCards integrated aliases for Hypokalemia:

Name: Hypokalemia 11 75 53 5 43 14
Potassium Deficiency 75 16 71 33
Potassium Deficiency Disorder 11 71
Potassium [k] Deficiency 33
Hypopotassaemia Syndrome 33
Hypokalaemic Syndrome 33
Potassium Depletion 33
Hypopotassaemia 33
Hypopotassemia 11
Hypokalaemic 33
Potassium 41

Classifications:



External Ids:

Disease Ontology 11 DOID:4500
MeSH 43 D007008
NCIt 49 C34939
ICD10 31 E87.6
ICD11 33 1586177000
UMLS 71 C0032827 C1514284

Summaries for Hypokalemia

MedlinePlus: 41 Potassium is a mineral that your body needs to work properly. It is a type of electrolyte. It helps your nerves to function and muscles to contract. It helps your heartbeat stay regular. It also helps move nutrients into cells and waste products out of cells. A diet rich in potassium helps to offset some of sodium's harmful effects on blood pressure. Many people get all the potassium they need from what they eat and drink. Sources of potassium in the diet include: Leafy greens, such as spinach and collards Fruit from vines, such as grapes and blackberries Root vegetables, such as carrots and potatoes Citrus fruits, such as oranges and grapefruit Your kidneys help to keep the right amount of potassium in your body. If you have chronic kidney disease, your kidneys may not remove extra potassium from the blood. Some medicines also can raise your potassium level. You may need a special diet to lower the amount of potassium that you eat.

MalaCards based summary: Hypokalemia, also known as potassium deficiency, is related to gitelman syndrome and hypokalemic periodic paralysis, type 1. An important gene associated with Hypokalemia is SLC12A3 (Solute Carrier Family 12 Member 3), and among its related pathways/superpathways are Glucose / Energy Metabolism and Metabolism of steroids. The drugs Prednisolone phosphate and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and skeletal muscle, and related phenotypes are homeostasis/metabolism and renal/urinary system

Wikipedia: 75 Hypokalemia is a low level of potassium (K+) in the blood serum. Mild low potassium does not typically... more...

Related Diseases for Hypokalemia

Diseases related to Hypokalemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2122)
# Related Disease Score Top Affiliating Genes
1 gitelman syndrome 32.4 SLC12A3 SLC12A1 REN KCNJ16 KCNJ1 CLCNKB
2 hypokalemic periodic paralysis, type 1 32.2 SLC12A3 REN KCNJ1 INS CACNA1S
3 apparent mineralocorticoid excess 32.1 SLC12A3 REN POMC NR3C2 KCNJ1 HSD11B2
4 bartter disease 31.9 SLC12A3 SLC12A1 REN KCNJ16 KCNJ1 CLCNKB
5 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 31.9 SLC12A3 SLC12A1 KCNJ16 KCNJ1 CLCNKB BSND
6 corticosterone methyloxidase type i deficiency 31.8 REN POMC CYP11B1
7 diarrhea 1, secretory chloride, congenital 31.8 CLCNKB CASR BSND
8 hyperaldosteronism, familial, type i 31.8 REN POMC NR3C2 HSD11B2 CYP17A1 CYP11B1
9 liddle syndrome 1 31.7 SLC12A3 SLC12A1 REN POMC NR3C2 KCNJ1
10 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 31.7 POMC CYP17A1 CYP11B1
11 renal tubular acidosis 31.3 SLC12A3 SLC12A1 REN AQP2
12 cardiac arrest 31.1 KCNH2 ADRB2 ACE
13 diabetes mellitus, ketosis-prone 31.1 REN INS ACE
14 graves disease 1 31.1 POMC INS CACNA1S
15 adenoma 31.1 REN POMC HSD11B2 CYP11B1 CASR
16 migraine with or without aura 1 31.0 REN POMC INS CACNA1S ADRB2 ACE
17 conn's syndrome 31.0 SLC12A3 SLC12A1 REN POMC NR3C2 KCNJ1
18 respiratory failure 30.9 REN INS ADRB2 ACE
19 alcohol use disorder 30.8 POMC INS ACE
20 intermediate coronary syndrome 30.8 REN INS ACE
21 adult syndrome 30.8 REN POMC INS HSD11B2
22 central pontine myelinolysis 30.8 REN POMC INS AQP2
23 hypoglycemia 30.7 POMC INS ADRB2 ACE
24 hypoaldosteronism 30.7 REN POMC ACE
25 renal artery atheroma 30.7 REN ACE
26 chondrocalcinosis 30.7 SLC12A3 REN CASR
27 microvascular complications of diabetes 3 30.7 REN INS ACE
28 hyperthyroidism 30.7 REN POMC INS
29 pseudohypoaldosteronism 30.7 SLC12A3 SLC12A1 REN NR3C2 KCNJ1
30 familial periodic paralysis 30.7 SLC12A3 INS CACNA1S
31 third-degree atrioventricular block 30.7 REN KCNH2 ACE
32 transient cerebral ischemia 30.7 REN INS ACE
33 renovascular hypertension 30.6 REN NR3C2 ACE
34 acute myocardial infarction 30.6 REN NR3C2 INS ACE
35 adrenal adenoma 30.5 REN POMC NR3C2 HSD11B2 CYP17A1 CYP11B1
36 sleep disorder 30.5 REN POMC INS ACE
37 interstitial nephritis 30.5 REN MT-TF ACE
38 kidney disease 30.5 SLC12A3 SLC12A1 REN NR3C2 INS CASR
39 heart valve disease 30.5 REN NR3C2 INS ACE
40 premenstrual tension 30.5 REN POMC
41 retinal vascular disease 30.5 REN INS ACE
42 urinary tract infection 30.4 REN NR3C2 INS ACE
43 nephrocalcinosis 30.4 SLC12A3 SLC12A1 KCNJ1 HSD11B2 CLCNKB CASR
44 peripheral vascular disease 30.4 REN INS ACE
45 nephrolithiasis 30.3 SLC12A1 KCNJ1 INS CLCNKB CASR BSND
46 chronic kidney disease 30.3 REN NR3C2 INS CASR BSND AQP2
47 congestive heart failure 30.3 REN NR3C2 INS AQP2 ADRB2 ACE
48 intracranial hypertension 30.3 REN POMC ACE
49 urinary tract obstruction 30.3 REN AQP2 ACE
50 sensorineural hearing loss 30.3 SLC12A1 KCNJ16 KCNJ1 CLCNKB CASR BSND

Graphical network of the top 20 diseases related to Hypokalemia:



Diseases related to Hypokalemia

Symptoms & Phenotypes for Hypokalemia

MGI Mouse Phenotypes related to Hypokalemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ACE ADRB2 AQP2 BSND CACNA1S CASR
2 renal/urinary system MP:0005367 10.35 ACE ADRB2 AQP2 BSND CASR CLCNKB
3 growth/size/body region MP:0005378 10.27 ACE ADRB2 AQP2 BSND CACNA1S CASR
4 cardiovascular system MP:0005385 10.22 ACE ADRB2 BSND CACNA1S CLCNKB CYP11B1
5 behavior/neurological MP:0005386 10.16 ACE ADRB2 AQP2 BSND CACNA1S CASR
6 muscle MP:0005369 10.11 ADRB2 CACNA1S CASR CYP11B1 HSD11B2 INS
7 adipose tissue MP:0005375 10.03 ACE ADRB2 CACNA1S CLCNKB CYP11B1 CYP17A1
8 hematopoietic system MP:0005397 9.97 ACE ADRB2 AQP2 BSND CASR CLCNKB
9 mortality/aging MP:0010768 9.86 ACE AQP2 BSND CACNA1S CASR CLCNKB
10 integument MP:0010771 9.28 ADRB2 AQP2 CACNA1S CASR CLCNKB INS

Drugs & Therapeutics for Hypokalemia

Drugs for Hypokalemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
6
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9 4872
7
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
8
Lactitol Approved, Investigational Phase 4 585-86-4 157355
9
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
10
Azithromycin Approved Phase 4 83905-01-5 447043
11
Licorice Approved Phase 4
12
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
13
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
14
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
15
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
16
Losartan Approved Phase 4 114798-26-4 3961
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
18
Sodium fluoride Approved Phase 4 7681-49-4
19
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
20
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
21
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
22
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
23
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
24
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
25
Ethanol Approved Phase 4 64-17-5 702
26
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
27
Phenol Approved, Experimental Phase 4 108-95-2 996
28
Glycerin Approved, Investigational Phase 4 56-81-5 753
29
Thymol Approved Phase 4 89-83-8 6989
30
Atenolol Approved Phase 4 29122-68-7 2249
31
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
32
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
33
Amlodipine Approved Phase 4 88150-42-9 2162
34
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
35
Lutetium Lu 177 dotatate Approved, Investigational Phase 4 437608-50-9 76966897
36
Petrolatum Approved, Investigational Phase 4 8009-03-8
37
Acetaminophen Approved Phase 4 103-90-2 1983
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
39
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
40
Lysine Approved, Nutraceutical Phase 4 56-87-1 5962
41
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
42
Canrenone Investigational Phase 4 976-71-6 13789
43 Antineoplastic Agents, Hormonal Phase 4
44 glucocorticoids Phase 4
45
Methylprednisolone Acetate Phase 4 584547
46
Ketorolac Tromethamine Phase 4
47 Anti-Arrhythmia Agents Phase 4
48 Antihypertensive Agents Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Adrenergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 300)
# Name Status NCT ID Phase Drugs
1 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
2 Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl for Correction of Hypokalemia in Hospitalized Patients Unknown status NCT02721095 Phase 4
3 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
4 A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence Unknown status NCT03007160 Phase 4 Potassium Citrate Extended-release Tablets
5 Effectiveness of Pre-surgical Hand Washing in Reducing Bacterial Load, Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate Unknown status NCT04683146 Phase 4 Hand antisepsis with Propanolol- 1 60%.;Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.
6 Effect of Diclofenac Potassium Versus Prednisolone as a Premedication on Post-endodontic Pain and Pulpal Interleukin (IL)-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Clinical Trial Unknown status NCT04608981 Phase 4 Prednisolone 30 mg;Diclofenac Potassium 50mg Tab;Placebo
7 Evaluation of Trans-mucosal Bio-adhesive Discs of Diclofenac Potassium on the Anesthetic Success and Postoperative Pain in Patients With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial Unknown status NCT04585438 Phase 4 Diclofenac Potassium
8 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
9 Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial Completed NCT00718068 Phase 4 Sterile Potassium Chloride Concentrate
10 Effect of Licorice and Hydrochlorothiazide on Plasma Potassium Completed NCT00605202 Phase 4 Hydrochlorothiazide
11 Fluid Therapy in Acutely Ill Children - a Randomized Controlled Trial Completed NCT02926989 Phase 4 Plasmalyte Glucos 50 mg/mL;0.45% saline in 5% dextrose
12 Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome) Completed NCT02297048 Phase 4
13 GRIP-COMPASS Trial: Computer-driven Glucose and Potassium Regulation Program in Intensive Care Patients With COMparison of PotASSium Targets Within normokAlemic Range Completed NCT01085071 Phase 4 Potassium Chloride
14 TOnicity of Perioperative Maintenance SoluTions - Part 1: Thoracic Surgery Completed NCT03080831 Phase 4 NaCl 0.9% in Glucose 5% + 40mmol/L Potassium;Glucion 5%
15 Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose Completed NCT00675987 Phase 4 losartan;Placebo control
16 A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Diclofenac Potassium Oral Solution in Pediatric Subjects (Ages 2-12 Years) With Mild to Moderate Acute Pain Completed NCT02287350 Phase 4 diclofenac potassium oral solution
17 Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal: A Pilot Study Completed NCT01930370 Phase 4 Bicarbonate hemodialysis solution (low concentration);Bicarbonate hemodialysis solution (high concentration)
18 Comparison of Efficacy of Bismuth Potassium Citrate, Pectin Bismuth Capsules, and Pectin Bismuth Granules in the Treatment of Helicobacter Pylori (Hp) First-line Quadruple Regimen: a Multicenter, Randomized, Prospective, Comparative Clinical Trial Completed NCT04209933 Phase 4 Bismuth potassium citrate containing quadruple therapy;Colloidal pectin bismuth capsules containing quadruple therapy;Colloidal pectin bismuth particles A quadruple therapy;Colloidal pectin bismuth particles B quadruple therapy
19 A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients Completed NCT00496834 Phase 4 losartan potassium;Comparator: carvedilol;Comparator: losartan (+) hydrochlorothiazide (HCTZ);Comparator: carvedilol (+) hydrochlorothiazide
20 An Open-Label Study of the Safety and Efficacy of Zipsor® (Diclofenac Potassium) Liquid Filled Capsules in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute Pain Completed NCT01982539 Phase 4 Zipsor®
21 A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years) Completed NCT02287376 Phase 4 Diclofenac Potassium for Oral Solution
22 Evaluation Of Fluoride Uptake By Dentine Following Pretreatment With Silver Diamine Fluoride And Potassium Iodide Under Resin Modified Glass Ionomer Restoration Versus Resin Modified Glass Ionomer Restoration Alone In Carious Primary Molars: (In Vitro Study) Completed NCT04777968 Phase 4 Silver diamine fluoride
23 Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension Completed NCT02653560 Phase 4 Potassium chloride powder;Potassium magnesium Citrate (KMgCit);Potassium citrate powder;Placebo
24 Randomized, Placebo-Controlled Evaluation of Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Completed NCT00765635 Phase 4 drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
25 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
26 Sodium-Potassium Blood Pressure Trial in Children Completed NCT00000521 Phase 4
27 Effectiveness of Pre-surgical Hand Washing in Reducing Bacterial Load, Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate Completed NCT04454619 Phase 4 Hand antisepsis with Clorhexidine and solution
28 Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial Completed NCT00610324 Phase 4 Chlorhexidine gluconate;Potassium permanganate
29 The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension Completed NCT00185094 Phase 4 Olmesartan medoxomil;Losartan potassium;Atenolol
30 A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain Completed NCT01666197 Phase 4 diclofenac potassium 25 mg tablet;placebo
31 A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects Completed NCT00949884 Phase 4 olmesartan medoxomil;Placebo;losartan potassium
32 Oral Potassium Supplementation in Healthy Men - Interactions With the Renin-angiotensin-aldosterone System and the Sympathetic Nervous System Completed NCT02380157 Phase 4 Kaleorid, 750mg (trade name), Potassium chloride (active substance);Placebo
33 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
34 A Multicenter, Randomized, Open Label Comparative Study Of Azithromycin Extended Release (ZMAX) Versus Amoxicillin/Clavulanate Potassium In Subjects With Acute Bacterial Sinusitis (ABS) In A Physician Practice Environment Completed NCT00367120 Phase 4 Azithromycin Extended Release;Amoxicillin/Clavulanate
35 A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients. Completed NCT00157963 Phase 4 MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks
36 Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome Completed NCT01384656 Phase 4 GIK solution
37 Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial Completed NCT01784445 Phase 4 Ceftazidime
38 Randomized Clinical Trial to Evaluate the Efficacy of Nano-hydroxyapatite Combined With the Potassium Nitrate for the Treatment of Dental Sensitivity Completed NCT02895321 Phase 4
39 Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter Completed NCT01818583 Phase 4 Potassium chloride;Glucose 50 MG/ML
40 Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis Completed NCT01329042 Phase 4 Potassium-sodium citrate
41 Arrhythmia Prevention in High Risk Cardiovascular Patients Using Targeted Potassium Levels Recruiting NCT03833089 Phase 4
42 Comparison of Potassium Binders in the ER Recruiting NCT04585542 Phase 4 Polyethylene Glycol 3350;Sodium Polystyrene Sulfonate Oral Suspension [SPS];Patiromer;Sodium zirconium cyclosilicate
43 Prevalence and Incidence of Dyskalemia in Hypertensive Patients Initiating a Fixed Dose Combination Pill of Telmisartan and Amlodipine Recruiting NCT05155436 Phase 4 Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
44 A Prospective, Randomized, Multi-Center, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia Following Augmentation of Dialysate Potassium Recruiting NCT05535920 Phase 4 LOKELMA 5 GM Powder for Oral Suspension
45 A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM) Recruiting NCT05211154 Phase 4 Diclofenac Potassium 50Mg/Pkt Oral Pwdr;Rimegepant 75 MG
46 A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment Recruiting NCT04524442 Phase 4 arginine/lysine
47 Comparative Evaluation of Staining Potential and Caries Arresting Effect of Silver Diamine Fluoride⁄Potassium Iodide and Silver Diamine Fluoride in Carious Primary Anterior Teeth Active, not recruiting NCT04196829 Phase 4 silver diamine fluoride ⁄ potassium Iodide;Silver Diamine Fluoride
48 The Impact of 4% Sodium Bicarbonate Additive During Potassium Chloride Replacement on Pain and Incidence of Phlebitis for Adult Patients in a Medical Surgical Unit: A Randomized Double Blinded Controlled Study Terminated NCT02082717 Phase 4 potassium chloride replacement;Experimental - 4% Sodium Bicarbonate
49 A Comparative Double Blind, Double Dummy, Randomized Study on the Effectiveness of Diclofenac Potassium vs. Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections Terminated NCT01019980 Phase 4 Diclofenac potassium;Acetaminophen
50 The Evaluation of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery Withdrawn NCT04384679 Phase 4

Search NIH Clinical Center for Hypokalemia

Cochrane evidence based reviews: hypokalemia

Genetic Tests for Hypokalemia

Anatomical Context for Hypokalemia

Organs/tissues related to Hypokalemia:

MalaCards : Kidney, Heart, Skeletal Muscle, Smooth Muscle, Liver, Brain, Prostate

Publications for Hypokalemia

Articles related to Hypokalemia:

(show top 50) (show all 39637)
# Title Authors PMID Year
1
Remodelling of potassium currents underlies arrhythmic action potential prolongation under beta-adrenergic stimulation in hypertrophic cardiomyopathy. 41
36058298 2022
2
Dietary Potassium Intake and Risk of Diabetes: A Systematic Review and Meta-Analysis of Prospective Studies. 41
36432472 2022
3
A Method for Estimating 24 h Urinary Sodium and Potassium Excretion by Spot Urine Specimen in Stroke Patients. 41
36235755 2022
4
Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. 53 62
20119883 2010
5
Feline primary hyperaldosteronism. 53 62
20219494 2010
6
Juxtaglomerular cell tumor of the kidney--a new classification scheme. 53 62
19914097 2010
7
Distal potassium handling based on flow modulation of maxi-K channel activity. 53 62
19448535 2009
8
Analysis of claudin genes in pediatric patients with Bartter's syndrome. 53 62
19538297 2009
9
Bartter's syndrome with type 2 diabetes mellitus. 53 62
19251537 2009
10
The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2. 53 62
19150652 2009
11
Diagnostic accuracy of adrenal venous sampling in comparison with other parameters in primary aldosteronism. 53 62
18497447 2008
12
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. 53 62
18645193 2008
13
[Severe hypokalemia after holidays return]. 53 62
19055123 2008
14
Gitelman syndrome. 53 62
18667063 2008
15
Selection of patients for surgery for primary aldosteronism. 53 62
18307754 2008
16
Changes of liver and muscle enzymes activity in patients with rigor. 53 62
18249306 2008
17
Reninoma: case report and literature review. 53 62
18192852 2008
18
[11beta-hydroxysteroide dehydrogenases. Recent advances]. 53 62
17368420 2007
19
Novel mutations in the SLC12A3 gene causing Gitelman's syndrome in Swedes. 53 62
17654016 2007
20
Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. 53 62
17314322 2007
21
[Clinical significance of thiazide-sensitive Na-Cl cotransporter gene by mutational analysis]. 53 62
17511264 2007
22
A compound heterozygous mutation in the CYP17 (17alpha-hydroxylase/17,20-lyase) gene in a Chinese subject with congenital adrenal hyperplasia. 53 62
17379008 2007
23
P450c17 deficiency: clinical and molecular characterization of six patients. 53 62
17192295 2007
24
Severe hypokalemia, rhabdomyolysis, muscle paralysis, and respiratory impairment in a hypertensive patient taking herbal medicines containing licorice. 53 62
17473492 2007
25
Loss of consciousness and hypokalemia in an elderly man with a mutation of the thiazide-sensitive Na-Cl cotransporter gene. 53 62
16966826 2006
26
Inherited renal tubulopathies associated with metabolic alkalosis: effects on blood pressure. 53 62
17275579 2006
27
Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels. 53 62
17042915 2006
28
Cortisol metabolism in hypertension. 53 62
16980198 2006
29
A patient with cystinosis presenting transient features of Bartter syndrome. 53 62
17172073 2006
30
Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. 53 62
16608889 2006
31
Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. 53 62
16778331 2006
32
A novel compound heterozygous mutation of K494_V495 deletion plus R496L and D487_F489 deletion in extreme C-terminus of cytochrome P450c17 causes 17alpha-hydroxylase deficiency. 53 62
16483711 2006
33
A novel mutation of the thiazide-sensitive sodium chloride cotransporter gene in a Japanese family with Gitelman syndrome. 53 62
16429844 2006
34
Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. 53 62
16142886 2005
35
VIPomas: an update in diagnosis and management in a series of 11 patients. 53 62
16001675 2005
36
A rare case of Gitelman's syndrome presenting with hypocalcemia and osteopenia. 53 62
16075932 2005
37
Evolution of diagnostic criteria for primary aldosteronism: why is it more common in "drug-resistant" hypertension today? 53 62
15527695 2004
38
G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. 53 62
15480096 2004
39
Apparent mineralocorticoid excess syndrome: an overview. 53 62
15761540 2004
40
The syndromes of low-renin hypertension: "separating the wheat from the chaff". 53 62
15761538 2004
41
[From gene to diseases; hypokalemic periodic paralysis]. 53 62
15185439 2004
42
Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. 53 62
14715827 2004
43
Stimulation of NHE3 in OKP cells by an autocrine mechanism. 53 62
14752245 2004
44
P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. 53 62
14671162 2003
45
High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. 53 62
14597859 2003
46
[Chondrocalcinosis and hypomagnesaemia in a patient with a new mutation in the gene of the thiazide-sensitive Na-Cl cotransporter]. 53 62
15002785 2003
47
Successful treatment of primary aldosteronism due to computed tomography-negative microadenoma. 53 62
14516402 2003
48
Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. 53 62
12788846 2003
49
Hypertension and the cortisol-cortisone shuttle. 53 62
12788832 2003
50
A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. 53 62
12714866 2003

Variations for Hypokalemia

ClinVar genetic disease variations for Hypokalemia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 77 genes DEL Pathogenic
1684639 GRCh37:
GRCh38: 22:18948676-21110520
2 MT-TF NC_012920.1(MT-CYB):m.591C>T SNV Pathogenic
1177637 GRCh37: MT:591-591
GRCh38: MT:591-591
3 SLC12A3 NM_001126108.2(SLC12A3):c.2221G>A (p.Gly741Arg) SNV Pathogenic
208612 rs138977195 GRCh37: 16:56921879-56921879
GRCh38: 16:56887967-56887967
4 SLC12A3 NM_001126108.2(SLC12A3):c.457G>A (p.Val153Met) SNV Uncertain Significance
523358 rs779074538 GRCh37: 16:56902236-56902236
GRCh38: 16:56868324-56868324
5 CLDN10 NM_006984.5(CLDN10):c.431C>T (p.Thr144Met) SNV Uncertain Significance
694635 rs374187735 GRCh37: 13:96212684-96212684
GRCh38: 13:95560430-95560430
6 MT-TF NC_012920.1(MT-CYB):m.643A>G SNV Uncertain Significance
689830 rs1603218472 GRCh37: MT:643-643
GRCh38: MT:643-643

Expression for Hypokalemia

Search GEO for disease gene expression data for Hypokalemia.

Pathways for Hypokalemia

Pathways related to Hypokalemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.16 KCNH2 INS CYP17A1 AQP2
2
Show member pathways
12.11 POMC INS HSD11B2 CYP17A1 CYP11B1
3 11.98 KCNJ16 KCNJ1 KCNH2 CACNA1S
4
Show member pathways
11.79 REN POMC INS ACE
5
Show member pathways
11.64 REN NR3C2 ACE
6
Show member pathways
11.24 POMC HSD11B2 CYP17A1 CYP11B1
7 10.48 SLC12A3 SLC12A1 KCNJ1 CLCNKB BSND

GO Terms for Hypokalemia

Cellular components related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.46 ACE ADRB2 AQP2 BSND CACNA1S CASR
2 membrane GO:0016020 10.46 ACE ADRB2 AQP2 BSND CACNA1S CASR
3 plasma membrane GO:0005886 9.7 SLC12A3 KCNH2 CLCNKB CASR BSND AQP2
4 plasma membrane GO:0005887 9.7 SLC12A3 KCNH2 CLCNKB CASR BSND AQP2

Biological processes related to Hypokalemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.92 ACE CYP11B1 POMC REN
2 transmembrane transport GO:0055085 9.91 SLC12A3 SLC12A1 KCNH2 CLCNKB CACNA1S AQP2
3 regulation of monoatomic ion transmembrane transport GO:0034765 9.91 KCNJ16 KCNJ1 KCNH2 CLCNKB CACNA1S
4 monoatomic ion transmembrane transport GO:0034220 9.88 SLC12A1 KCNJ16 KCNJ1 KCNH2 CLCNKB
5 potassium ion transport GO:0006813 9.85 SLC12A1 KCNJ16 KCNJ1 KCNH2
6 potassium ion homeostasis GO:0055075 9.85 SLC12A3 SLC12A1 KCNH2
7 angiotensin maturation GO:0002003 9.81 REN ACE
8 monoatomic ion transport GO:0006811 9.81 CACNA1S CLCNKB KCNH2 KCNJ1 KCNJ16 SLC12A1
9 glucocorticoid biosynthetic process GO:0006704 9.8 CYP17A1 CYP11B1
10 cortisol metabolic process GO:0034650 9.78 HSD11B2 CYP11B1
11 chloride transmembrane transport GO:1902476 9.65 SLC12A3 SLC12A1 CLCNKB CASR BSND
12 potassium ion import across plasma membrane GO:1990573 9.32 SLC12A3 SLC12A1 KCNJ16 KCNJ1 KCNH2

Molecular functions related to Hypokalemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium:chloride symporter activity GO:0015379 9.62 SLC12A3 SLC12A1
2 sodium:potassium:chloride symporter activity GO:0008511 9.46 SLC12A3 SLC12A1
3 inward rectifier potassium channel activity GO:0005242 9.43 KCNJ16 KCNJ1 KCNH2
4 chloride:monoatomic cation symporter activity GO:0015377 9.26 SLC12A3 SLC12A1
5 voltage-gated monoatomic ion channel activity GO:0005244 9.02 KCNJ16 KCNJ1 KCNH2 CLCNKB CACNA1S

Sources for Hypokalemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....